Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.28

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€4.66M

Enterprise Value€29.19

Total Cash (Recent Filing)€6.93M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageReported zero total debt across recent years reduces fixed financing obligations and lowers short-term refinancing risk. For an early-stage biotech this preserves strategic optionality for non-dilutive deals or milestone-based partnerships and limits interest burdens while clinical programs progress.

Focused Therapeutic PipelineA clear, concentrated focus on sickle cell disease targets a defined unmet medical need with structural demand and potential for durable adoption if clinical success is achieved. Focused R&D priorities can improve resource allocation, expedite development decisions, and attract disease-area partners or specialized investors.

Improved Equity PositionAn improvement to a positive equity base suggests recent recapitalization or financings that strengthened reported net assets. This provides a larger buffer against insolvency risk, supports near-term operations and trial activity, and indicates the company has been able to access capital markets or investor support when needed.

Bears Say

Pre-revenue ProfileAbsence of product revenue over multiple years means the company cannot self-fund activities and remains fully reliant on external financing. This structural reality amplifies binary clinical and regulatory risks, elongates the path to sustainable cash generation, and elevates investor dependence on successful trials or partner deals.

Persistent Cash BurnConsistent negative operating and free cash flow, with worsening burn to ~-SEK 18.1m in 2025, creates ongoing financing requirements. Over a 2–6 month horizon this structural cash deficit raises dilution risk, constrains discretionary R&D spending, and forces reliance on capital markets or partnerships to sustain clinical programs.

Sustained Operating LossesMaterial and persistent operating losses indicate no clear trajectory to profitability in the near term. This diminishes internal capacity to invest, pressures future financing needs, and leaves long-term viability contingent on successful development milestones or external funding events rather than operating cash generation.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.28 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €4.66M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 8 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.